Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-eluting stents.

A Chieffo1, A Colombo

  • 1Interventional Cardiology EMO, Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy.

Minerva Cardioangiologica
|October 18, 2002
PubMed
Summary
This summary is machine-generated.

Drug-eluting stents, using drugs like rapamycin and paclitaxel, show promise in preventing restenosis after coronary interventions. Ongoing studies will confirm their long-term effectiveness in diverse patient populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting transradial approach.

Panminerva medica·2014
Same author

Defining a new standard for IVUS optimized drug eluting stent implantation: the PRAVIO study.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2009
Same author

Bioabsorbable and biocompatible stents. Is a new revolution coming?

Minerva cardioangiologica·2008
Same author

Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT).

International journal of cardiology·2008
Same author

Revascularization of unprotected left main coronary artery disease with percutaneous coronary intervention: the role of drug-eluting stents.

Minerva cardioangiologica·2008
Same author

Applying intravascular ultrasound to optimize the placement of coronary drug-eluting stents.

Minerva cardioangiologica·2005
Same journal

Mechanistic factors of cardiovascular diseases.

Minerva cardioangiologica·2020
Same journal

Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.

Minerva cardioangiologica·2020
Same journal

Features of degenerative mitral valve prolapse in the North East of China: repair characteristics, and short-term follow-up results.

Minerva cardioangiologica·2020
Same journal

Myocardial revascularization in chronic coronary syndromes: does viability matter?

Minerva cardioangiologica·2020
Same journal

Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?

Minerva cardioangiologica·2020
Same journal

Heart and endurance sports: excesses are often unhealthy.

Minerva cardioangiologica·2020
See all related articles

Area of Science:

  • Interventional Cardiology
  • Biomedical Engineering
  • Pharmacology

Background:

  • Percutaneous coronary intervention (PCI) limitations include restenosis, necessitating advanced treatments.
  • Drug-eluting stents (DES) emerged as a significant advancement over traditional balloon angioplasty and bare metal stents.
  • Restenosis, the re-narrowing of arteries after PCI, remains a primary clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy of drug-eluting stents in reducing restenosis following coronary interventions.
  • To assess the role of antiproliferative drugs, specifically rapamycin and paclitaxel, delivered via stents.
  • To review the current evidence and future directions for drug-eluting stent technology.

Main Methods:

  • Review of pilot and randomized clinical trials investigating drug-eluting stents.

Related Experiment Videos

  • In vitro and in vivo studies on the mechanisms of action of rapamycin and paclitaxel.
  • Analysis of promising data from paclitaxel-eluting stents.

    • Main Results:

    • Rapamycin-eluting stents demonstrated inhibition of smooth muscle cell proliferation and reduced neointima formation.
    • Pilot and randomized studies indicated rapamycin-eluting stents could eliminate restenosis.
    • Paclitaxel-eluting stents also show promising antiproliferative activity.

    Conclusions:

    • Drug-eluting stents, particularly those with rapamycin and paclitaxel, represent a major advancement in interventional cardiology.
    • Further clinical studies and long-term follow-up are essential to fully establish the potential of DES.
    • Real-world data on diverse lesion types and extended follow-up are crucial for widespread adoption.